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A n explosion of knowledge about the genetic and genomic bases for rare and common diseases has provided a framework for revolutionizing the practice of medicine. Achieving the reality of a genomic medicine era requires that basic discoveries are effectively translated into clinical practice through implementation of genetic and genomic testing. Clinical genetic tests have become routine for many inherited disorders and can be regarded as the standard of care in many circumstances, including disorders affecting the cardiovascular system. New high-throughput methods for determining the DNA sequence of all coding exons or complete genomes are being adopted for clinical use to expand the speed and breadth of genetic testing. Along with these extraordinary advances have emerged new challenges to practicing physicians for understanding when and how to use genetic testing and how to appropriately interpret test results. This review will acquaint readers with general principles of genetic testing, including newer technologies, test interpretation, and pitfalls. The focus is on testing genes responsible for monogenic disorders and on other emerging applications such as pharmacogenomic profiling. The discussion is extended to the new paradigm of direct-to-consumer genetic testing and the value of assessing genomic risk for common diseases.
Logistical Considerations for Genetic Testing
Genetic testing is a specialized diagnostic procedure that can be performed by commercial and research laboratories. However, in the United States, clinical genetic testing laboratories must meet stringent criteria for quality standards that conform to the federal Clinical Laboratory Improvement Amendments (referred to as CLIA). 1 Most research laboratories operate without Clinical Laboratory Improvement Amendments certification, and data generated in this setting are not strictly appropriate for inclusion in patient medical records or for making clinical decisions. Discoveries made by research laboratories should be confirmed by a Clinical Laboratory Improvement Amendments-certified clinical genetics laboratory if the results are meaningful to patient care.
Unlike commonly used laboratory assays, genetic testing should be performed after the patient is informed about the potential risks, benefits, and limitations. Involvement of a genetics counselor is ideal in circumstances in which either physician time or knowledge is limited. The potential negative impact of learning the results of a genetic test must be anticipated. Patients should be properly educated and carefully counseled about their long-term risks of having a genetic condition without inciting excessive apprehension by implying that genotype is an absolute predictor of disease. Physicians should also be sensitive to the potential socioeconomic fallout (eg, insurability) from a genetic diagnosis and vigorously guard the confidentiality of test results. In the United States, the Genetic Information Nondiscrimination Act prohibits workplace and health insurance discrimination based on genetic predisposition, but this sensitive information should be protected nonetheless.
Indications for Genetic Testing
Genetic testing is performed under a variety of circumstances and applied at various time points from before life begins to after death occurs ( Table 1 ). The most common scenarios for clinical genetic testing for cardiovascular disorders occur beyond the perinatal period and include diagnostic, presymptomatic, and postmortem testing. Diagnostic testing undertakes the primary discovery of genetic defects by screening a panel of genes previously associated with a specific disease. Directed genetic testing (eg, detection of specific mutation or genomic variant) is performed when there is a known familial risk for a disease and a previously identified mutation in the parents or other first-degree relative. Postmortem genetic testing is increasingly performed in the evaluation of sudden unexplained death, especially in the young, and yields positive findings in up to a quarter of autopsies. 2, 3 Preimplantation genetic testing is performed on in vitro fertilized embryos to guide the selection of unaffected embryos for transfer to a recipient uterus. 4 Although risk for cardiovascular disorders is not typically determined, there have been successful uses of preimplantation genetic diagnosis in cases of Holt-Oram syndrome 5, 6 and familial cardiomyopathy. 7 Direct-to-consumer genetic testing is discussed later.
A freely available Internet resource, GeneTests, provides a searchable database of clinical genetic testing laboratories, specialty clinics, and other relevant information (Table 2 ). 8 The current database consists of entries from >600 laboratories worldwide, offering tests for an aggregate of >3000 genetic conditions. A variety of test types are indexed, including molecular (eg, DNA sequence), cytogenetic, and biochemical assays. The clinic directory has information for >1000 genetics clinics internationally. GeneTests can be searched by using disease or gene names to retrieve a listing of laboratories performing specific tests and their contact information. The database can also be searched to find laboratories and specialty clinics within a specific region.
Information in GeneTests has recently transitioned to a resource hosted by the National Center for Biotechnology Information, the Genetic Testing Registry, which is a repository for testing information provided by laboratories. Both GeneTests and the Genetic Testing Registry provide geneand disease-specific information derived in part from another resource, GeneReviews, a collection of expertly written and peer-reviewed articles on genes and genetic disorders. This site is also hosted by the National Center for Biotechnology Information. A similar searchable database, the UK Gene Testing Network, provides online access to a catalog of genetic tests provided by clinically accredited laboratories in the United Kingdom.
Several monogenic diseases primarily or secondarily affect the cardiovascular system (Table 3) . For many cardiovascular disorders in which mendelian inheritance has already been established, genetic testing may already be indicated, and guidelines have been published for the use and interpretation of genetic tests for many specific disorders, including channelopathies and familial cardiomyopathies. 9, 10 In other circumstances, an important step in determining which specific patients will benefit most from a genetic workup is distinguishing cases that arise from a single gene mutation or definable genomic defect from those with a more complex origin (eg, combined impact of multiple genetic, developmental, and environmental factors). Clinical evidence suggesting a single genetic locus origin may include familial segregation of the trait in a pattern Recognizing mendelian inheritance patterns requires the ascertainment of a thorough and reliable family history with construction of a multigeneration pedigree. However, this task requires considerable time and may not be practical for busy clinicians. Therefore, when physician time is limited, alternative strategies for acquiring family history data should be used that involve properly trained allied health professionals (eg, genetic counselors, nurse practitioners, physician assistants) who are familiar with the phenotype, computer or Internet resources developed for collecting family health history, or carefully compiled disease-specific survey tools. Nuances of mendelian inheritance such as incomplete penetrance (eg, the presence of a mutation does not correlate with disease in all cases) and subclinical disease expression may confound the interpretation of pedigree data. For these reasons, the involvement of genetic counselors or referral to a medical geneticist is highly recommended.
Extreme phenotypes may suggest a monogenic disorder even in the absence of a clear family history such as with de novo mutations. Unusually early onset of phenotypes that are more typically adult onset such as hypertensive stroke, coronary artery disease, heart failure, and sudden cardiac death should raise suspicion of a monogenic condition. Additional clinical features that may affect organs or tissues outside the cardiovascular system may herald the presence of a specific genetic or genomic syndrome.
Genetic testing may have value beyond establishing or confirming a particular diagnosis in the primary patient. Demonstrating a specific mutation or genomic defect provides an opportunity to offer targeted testing to relatives who may be affected by the same disease or are at risk on the basis of their shared genetic makeup. Collateral testing of first-degree relatives (eg, siblings, parents, offspring), referred to as cascade screening, can identify presymptomatic individuals who may benefit from additional diagnostic procedures or prophylactic therapy. Positive genetic test results may also help tailor therapy and provide a basis for reproductive genetic counseling.
Next-Generation Clinical Genetic Testing
An extensive technological repertoire exists to test DNA for a range of medically relevant genetic and genomic defects, ranging from single-nucleotide variants to chromosomal aberrations. Recent advances in DNA sequencing technology have greatly expanded the scope and capabilities of clinical genetic testing laboratories to discovery medically actionable mutations in cardiovascular disorders. 11, 12 Until the past few years, the standard sequencing platforms used the Sanger method, and this approach served as the "workhorse" for sequencing the human genome. The advent of next-generation sequencing brings a paradigm shift in the scale and complexity of clinical genetic testing, enabling laboratories to perform testing on large panels of disease-relevant genes, all coding exons (exome) or whole genomes. This has allowed genetic diagnoses in small families with rare disorders and discovery of novel disease-causing genes at much lower cost per nucleotide. In 2013, the US Food and Drug Administration granted marketing authorization for the first next-generation sequencer to be used for clinical genetic testing. 13 During the past 3 years, there has been an explosion in the number of reports demonstrating successful uses of exome and genome sequencing to uncover the genetic basis for Figure 1 . Illustration of steps involved in DNA capture and next-generation sequencing. Intact human genomic DNA is sheared into random, small fragments, and then synthetic adaptor sequences are added to the fragment ends. Next, the pool of adaptor-ligated DNA fragments is incubated with a complex mixture of biotinylated RNA "baits" designed to hybridize to all coding exons by complementary nucleic acid base pairing. After hybridization, targeted DNA regions are captured with the use of streptavidincoated magnetic beads, which selectively bind the biotinylated bait strands and simultaneously immobilize any bound DNA fragments. After washing to remove excess bait and unbound DNA, a library of captured DNA is prepared for sequencing. Finally, all captured DNA is sequenced a several-fold redundancy with a next-generation sequencer, and the data output is analyzed. Adapted from Bamshad et al 12 with permission from the publisher. Copyright © 2011, Macmillan Publishers Ltd. Authorization for this adaptation has been obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation. (Table I in the online-only Data Supplement). Accompanying these advances are new challenges for handling and interpreting massive quantities of data and managing discovery of medically actionable incidental findings.
Sequence capture technology, coupled with next-generation sequencing, has enabled 2 new genetic testing paradigms: simultaneous sequencing of multiple genes and whole-exome sequencing.
14 Figure 1 illustrates the general workflow of these approaches. Initially, genomic DNA is sheared into small fragments (typically 200-500 base pairs); then, these fragments of DNA are mixed with a capture reagent. The capture reagent is a solution mixture of thousands of synthetic DNA or RNA molecules designed with base-pair complementarity to all sequences within the target of interest (eg, all exons of a candidate gene panel or all coding exons in the genome). 12 For exome sequencing, the capture reagent will generally target ≈180 000 exons and ≈50 Mb or ≈1% of the entire human genome. The captured patient DNA is then sequenced on a next-generation sequencer, and an intensive bioinformatics analysis is performed to read the sequence (base calling), to assess data quality, to align sequences to a reference genome, and to call and annotate variants. Additional details on the technical aspects and limitations of exome sequencing have been described elsewhere. 12, 14 An adequate depth of coverage (eg, redundancy with which each nucleotide is sequenced) is necessary to ensure reliability and accuracy. Certain technical limitations can affect the analytic quality of exome data, and Sanger sequencing is often used to validate results and to eliminate false positives. Analysis of exome data to identify disease-associated variants is aided greatly by knowledge of family structure and by the collection of sequence data from first-degree relatives who are either affected or unaffected (Figure 2 ). Whole-genome sequencing may soon be sufficiently costeffective and time-efficient to warrant its use as the mainstay in next-generation clinical genetic testing. Although the costs of sequencing an entire human genome are falling rapidly, substantial challenges to data analysis remain that will slow widespread clinical implementation. 16 However, there is evidence that these challenges may be surmountable sooner than expected. A recent report demonstrated the feasibility of a rapid turnaround of genome sequencing results for determining the molecular diagnosis of a severe case of neonatal long-QT syndrome type 2 (KCNH2 mutation) in a clinical setting.
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Classifying Variants and Interpreting Test Results
Genetic variants identified by clinical genetic testing laboratories are classified according to defined schema to enable a concise language for describing the best estimate of the clinical significance of a reported sequence variation (Table 4 ). In 2008, the American College of Medical Genetics Laboratory Quality Assurance Committee recommended 6 interpretative categories of sequence variants to standardize laboratory reporting of genetic test results. 18 Two of these categories are intended for variants with the strongest supporting evidence for pathogenicity (disease causing) or lack of pathogenicity (not disease causing). Other categories provide descriptors for variants with less certain clinical significance. A similar 5-tiered scheme was proposed by the International Agency for Research on Cancer to classify variants detected in subjects at risk for hereditary cancer syndromes. 19 The International Agency for Research on Cancer scheme additionally assigns quantitative probability ranges for each category. Commercial genetic testing laboratories may deploy additional derivatives of these classification schemes for standardized reporting. Importantly, evidence for or against pathogenicity of a given variant may evolve with new information or experimental data. Certain variants once deemed pathogenic may require reclassification because of new findings. 20, 21 Allele frequency in reference populations is typically used to distinguish common genetic variants from rare, candidate mutations. Resources for ascertaining population-based allele frequencies are listed in Table 2 . The Single Nucleotide Polymorphism Database is a freely available catalog of genetic Definitely pathogenic: >0.99 probability of being pathogenic Likely pathogenic: 0.95-0.99 probability of being pathogenic Uncertain: 0.05-0.949 probability of being pathogenic Likely not pathogenic: 0.001-0.049 probability of being pathogenic Not pathogenic: <0.001 probability of being pathogenic More recently, databases of human genome and exome sequences have been curated to determine variant frequencies. The 1000 Genomes Project archives low-coverage genome sequences on >1000 individuals without disclosed phenotypic information. 22 Similarly, the Exome Sequencing Project, funded by a Grand Opportunity grant from the National Heart, Lung, and Blood Institute, has populated the Exome Variant Server with data deduced from exome sequencing of >6500 individuals. 23 The Human Genetic Variation Browser database includes exome data obtained from 1208 Japanese subjects. These resources can be used to determine whether a discovered variant is novel and therefore likely disease-causing by virtue of its absence or rarity in the general population. Certain variants with known association with specific genetic disorders may be captured by these large-scale projects, but the significance of these findings is uncertain. The presence of a genetic variant in a reference database does not necessarily exclude its potential pathogenicity, especially when the observed allele frequency is below the estimated population frequency of the disease. For example, the congenital long-QT syndrome has been estimated to affect 1 in 2500 live births on the basis of a large-scale neonatal ECG screening study coupled with candidate gene mutation discovery in nearly 45 000 Italian neonates. 24 In contrast, other variants reported as associated with disease in familial cardiomyopathy and certain arrhythmic disorders are present in reference databases at frequencies higher than expected on the basis of the population prevalence of the respective phenotypes. [25] [26] [27] [28] These findings suggest the need for caution in interpreting incidentally discovered variants without stringent criteria for assigning pathogenicity (eg, segregation with phenotype in >1 family, functional evidence of deleterious consequences).
Variants of Unknown Clinical Significance
Results from clinical genetic testing may be confounded by the discovery of variants of unknown significance (VUS) for which data are insufficient to establish whether a particular variant predisposes to a disease. With the expanded use of exome/genome data in clinical medicine, interpreting VUS will become a larger challenge, especially when variants in genes associated with monogenic disorders are incidentally discovered and reported. This problem is particularly vexing for most genetic disorders that have a high level of allelic heterogeneity and a preponderance of private mutations. Additional evidence should be sought when possible to more firmly establish the relationship with disease risk in a family testing positive for a VUS. Segregation of the VUS among affected and unaffected family members may provide additional support for disease association, although this may be difficult to ascertain in small families and disorders with recessive inheritance or incomplete penetrance. Laboratory research to establish whether a VUS has deleterious consequences may offer additional clues to pathogenicity, but these are not standardized assays that yield results suitable for clinical decision making. Nonetheless, collaboration between clinicians and researchers provides an avenue to decrypt the growing burden of VUS.
Several computational strategies have been developed to help predict the potential effects of genetic variants on protein function in the research setting. Two of the more widely used methods are PolyPhen-2 and SIFT (sorting intolerant from tolerant). SIFT uses protein sequence homology to assess the likelihood that a position-specific amino acid substitution will be damaging on the basis of the premise that important residues will be conserved in the protein family throughout evolution. 29, 30 SIFT was originally developed through the use of prokaryotic gene mutation data but was later tested on a large set of annotated human mutation data. PolyPhen-2 uses protein sequence-based and structure-based features to make predictions. 31 Another approach, evolutionary diagnosis, featuring statistical models based on evolutionarily weighted training data, has been suggested to offer improved predictive power. 32 Newer, purportedly better methods have emerged recently, 33, 34 but no particular algorithm appears superior to all others. 35 Disease-specific models may have better performance. 36 Importantly, there have been few attempts to experimentally validate these in silico prediction models.
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Managing Negative Results and Incidental Findings
Interpretation of a negative genetic test in a symptomatic person is a significant challenge. A true-negative result (eg, technically successful but no pathogenic findings) may occur because the test does not target the causative gene, possibly because a previously unknown genetic culprit is involved or the test panel was not comprehensive. Theoretically, this phenomenon will occur less frequently when exome sequencing is used as the testing platform. False-negative results (eg, no pathogenic findings reported even when one exists in the targeted gene) have other causes such as location of a mutation outside the region interrogated by the test 38 and existence of types of mutations (eg, multi-exon deletion, duplication) missed by the most commonly used testing strategies that are designed for finding single-nucleotide changes. [39] [40] [41] Repeat testing may sometimes overcome false-negative results, especially when there is a high level of clinical suspicion. 42 The use of exome or genome sequencing may uncover medically actionable variants unrelated to the primary disorder that prompted the test. This point was illustrated by an examination of 1000 participants randomly selected from the 6500 subjects studied by the National Heart, Lung, and Blood Institute Exome Sequencing Project. 43 In a survey of pathogenic variants in 114 genes selected because of associations with medically actionable genetic conditions, the frequency of highly penetrant and actionable variants was 1.2% for individuals of African descent and 3.4% for subjects with European ancestry. Among the pathogenic variants identified were several in genes associated with familial cardiomyopathy and congenital arrhythmia susceptibility. This demonstration of the prevalence of incidental findings in exome data in a research setting has prompted considerable debate about the best practice for reporting and managing such information.
Recently, the American College of Medical Genetics Working Group on Incidental Findings in Clinical Exome and Genome Sequencing recommended that laboratories performing clinical sequencing seek and report mutations in 57 genes, including 30 genes responsible for cardiovascular phenotypes (Table 5) . 44, 45 These recommendations were designed to establish an initial reporting standard for laboratories engaged in exome/genome sequencing for genetic diagnosis. Inherent in the ethical framework within which these recommendations were based was the assumption that the ordering clinician would bear responsibility for obtaining informed consent from the patient, including pretest and posttest genetic counseling about the potential risks and benefits of testing. 46 The American College of Medical Genetics recommendations have been challenged on both scientific and ethical grounds 47, 48 but defended by emphasizing that incidental findings provide an opportunity for patient education and collaboration between patient and provider to define the best course of action. 49 A recent amendment to these recommendations by the American College of Medical Genetics suggests that patients should be given an opportunity to opt out of the analysis of medically actionable genetic variants at the time samples are sent for initial testing. 50 Genetic counselors may have special value in helping patients make such decisions.
Pharmacogenomic Profiling
Clinical genetic testing can be applied to reveal genomic variants associated with interindividual differences in drug responses (eg, variable therapeutic efficacy or adverse effects). The term pharmacogenetics was originally coined as the study of unusual drug response traits exhibiting mendelian inheritance in families (eg, glucose-6-phosphate dehydrogenase deficiency [G6PD, Xq28], pseudocholinesterase deficiency [CHE1, 3q25], malignant hyperthermia susceptibility [RYR1, 19q13] ). In contrast, pharmacogenomics has been used to describe mainly population-based studies defining genes or loci associated with differences in drug responses among groups of unrelated individuals. Drug response variability is often explainable by differences in either pharmacokinetics (eg, drug metabolism for biotransformation or elimination) or pharmacodynamics (eg, response of the target molecule). More than 125 US Food and Drug Administration-approved drugs have pharmacogenomic information in their labeling, including some with boxed warnings advising physicians to acquire specific genomic data on patients for whom the drug is being considered. The Clinical Pharmacogenetics Implementation Consortium, formed by the National Institutes of Healthfunded Pharmacogenomics Research Network, 51 has developed a series of evidence-based consensus guidelines to enable the translation of clinical genetic test results into actionable prescribing decisions for specific drugs. 52 The emergence of pharmacogenomics has offered new opportunities for achieving the goal of personalized medicine by using clinical testing for medically actionable variants, including drugs commonly prescribed for cardiovascular disorders. [53] [54] [55] Genetic testing may have value in predicting the efficacy of a specific drug therapy (eg, CYP2C19 genotyping in the setting of antiplatelet therapy with clopidogrel), 56 identifying individuals who are at risk for specific adverse reactions (eg, SLCO1B1 genotyping to assess risk of simvastatin-induced muscle toxicity), 57, 58 or determining initial dosage (VKORC1 and CYP2C9 genotyping for warfarin dosing). 59 Strategies for implementing pharmacogenomic testing in clinical settings either have adopted a 1-gene-at-a-time approach 60, 61 or have advocated for preemptive testing of multiple variants. [62] [63] [64] Decision support is essential for educating providers about the interpretation of test results and for presenting specific prescribing actions. Physician adoption and use of pharmacogenomics testing can be high in settings where point-of-care decision support is provided 65 but somewhat less effective when results are merely faxed to providers several days later. 66 Further research, including randomized, clinical trials such as those recently reported for oral anticoagulants, [67] [68] [69] is needed to determine the value of pharmacogenomic testing in clinical practice.
Testing for Complex Genetic Traits
Whereas genetic diagnostics have become routine and standard of care for many monogenic disorders, laboratory assessments of inherited risk for more common and genetically complex diseases are seldom performed in medical practice. 70 During the past decade, genome-wide association studies have mapped >1000 disease-susceptibility loci based on the common disease-common variant hypothesis, which posits that a major portion of risk for a common disease in populations is conferred by a limited number of common genetic variants. 71 A frequent observation made by genome-wide association studies is that common variants account for only a small proportion of population-attributable risk (estimated by an odds ratio with reported values often <1.5), and results from these population-based genomic studies have been difficult to translate into risk predictions for individuals.
The US Centers for Disease Control and Prevention have recently launched the Evaluation of Genomic Applications in Practice and Prevention initiative to establish and evaluate an evidence-based process for assessing applications of genomic technologies in the clinical setting. 72 Using this systematic approach, an evaluation of specific cardiovascular disease genomic risk variants in 29 candidate genes found only weak to moderate evidence supporting clinical validity. A possible exception was with the association of 9p21 variants with heart disease, which seemed more robust, although the estimated additional benefit of knowing genotype at this locus was judged as negligible. 73, 74 Further studies, including clinical trials, are needed to determine the impact of genomic risk testing on clinical outcomes, physician practice, patient behavior, and healthcare costs.
Despite the uncertain benefits to individuals undergoing genomic risk profiling, a few for-profit business ventures have capitalized on direct-to-consumer marketing of genomic testing. A leader in this emerging industry has been 23andMe, Inc (Mountain View, CA). Such companies market laboratory genetic testing and interpretive services for assessing genomic risk for specific diseases, pharmacogenomic profiling, and analysis of ancestry directly to consumers without requiring input from healthcare providers. 75 The intent of these services is to empower individuals with personal genomic information November 25, 2014 that might help improve health through lifestyle changes and more informed medical decision making. Collections of population-based genomic data also have enabled research opportunities. [76] [77] [78] Initial research on the impact of direct-to-consumer genomic testing suggests that there is little harm or benefit. 79, 80 The advent of direct-to-consumer genetic testing ignited considerable debate related to the medical value of the genomic risk discoveries on which these proprietary tests are based and on the accuracy of the data provided to consumers. 75, 81 Unlike other genetic diagnostics, which are classified as medical devices requiring US Food and Drug Administration approval, direct-to-consumer tests have not been subjected to regulation. In late 2013, after the launch of an aggressive campaign to sell its product, the US Food and Drug Administration ordered 23andMe to discontinue marketing its primary genomic profiling service. 82, 83 New regulatory regimens stimulated by these actions could affect other emerging genomic testing paradigms, including whole-genome sequencing.
Summary
Technical advances have ushered in a new era of genetically informed diagnosis that will affect both rare and common cardiovascular disorders. Understanding the capabilities and limitations of genetic testing in various clinical settings is vital to effectively translate the tsunami of medical breakthroughs generated during this genomic era into clinical practice. Accomplishing these goals will require changes in medical education, healthcare delivery systems, and medical informatics, as well as more informed patients and providers.
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